<\/p>\n
There’s a reason the world’s most patient investors love dividend stocks.<\/p>\n
Market movements heavily influence a stock’s capital-gains potential in a given year. But dividends are usually paid whether the broader market is up or down, and that dependability is a big reason to factor them in when buying stock.\u00a0<\/p>\n
“Dividends can provide not only income, but they may also accelerate the payback on investment,” Fidelity says.<\/p>\n
That logic plays out perfectly with Eli Lilly.<\/p>\n
A decade ago, Eli Lilly (LLY) was already a solid pharmaceutical company. But investors who bought early and held on didn’t just enjoy a massive stock price run-up. <\/p>\n
They quietly unlocked something even more rewarding, a yield-on-cost that has ballooned to 9%. That’s the kind of return that makes dividend stock investing click for a lot of people.<\/p>\n
Here’s how it happened.<\/p>\n
$1,000 in LLY stock became a 9% income machine<\/p>\n
In 2016, Eli Lilly shares traded at roughly $77, and a $1,000 investment would have bought you about 13 shares.<\/p>\n
At the time, the annual dividend was $2.04 per share. Those 13 shares would have generated $26.52 in annual dividend income, a yield of about 2.6% on your original investment. Nothing flashy, but solid.<\/p>\n
Fast-forward to today.<\/p>\n
Eli Lilly now pays $1.73 per share quarterly, or an annual dividend of $6.92 per share. Those same 13 shares you bought in 2016 now throw off roughly $90 in annual dividend income.<\/p>\n
Related: Eli Lilly\u2019s pill solves the biggest problem with weight loss<\/p>\n
That’s a yield-on-cost of 9%.<\/p>\n
Your original investment didn’t change. The number of shares didn’t change. But because Lilly kept raising its payout year after year, the income you collect on that initial $1,000 keeps growing.\u00a0<\/p>\n
This is the compounding magic that makes dividend stocks so powerful for long-term investors.<\/p>\n
Here’s a snapshot of LLY’s key dividend metrics: Annual dividend per share: $6.92Quarterly dividend per share: $1.73Current dividend yield: About 0.7%5-year dividend growth rate: Approximately 15.2% annuallyConsecutive years of dividend increases: 12Dividend growth since 2014: About 11% annually<\/p>\n
Since 2014, Eli Lilly has increased its dividend at an annual rate of 11%, and given an annual dividend expense of $6.2 billion, the company has plenty of room to keep raising its payout.<\/p>\n
In 2025, LLY reported free cash flow of $8.9 billion, indicating a payout ratio of almost 77%. However, FCF is projected to balloon to almost $47 billion by 2030.<\/p>\n
If Eli Lilly stock maintains a payout ratio of just 30%, its dividend could almost double over the next four years.\u00a0<\/p>\n
Lilly’s health care moat widens<\/p>\n
The dividend raises don’t happen in a vacuum and are backed by one of the most explosive growth stories in the pharmaceutical sector.<\/p>\n
In its first-quarter 2026 earnings call, Eli Lilly CEO Dave Ricks reported that revenue grew 56% compared to the same period in 2025, driven primarily by obesity and diabetes drugs Zepbound and Mounjaro, which together generated$12.8 billion in combined global revenue in Q1.\u00a0<\/p>\n
The company also raised its full-year 2026 revenue guidance to between $82 billion and $85 billion.Moreover, Lilly launched Foundayo in April, a first-of-its-kind oral GLP-1 drug approved for weight management.\u00a0Over 20,000 patients had already tried it within the first few weeks of launch, with 80% of those prescriptions going to patients who had never tried a GLP-1 therapy before.<\/p>\n
“During the quarter, we delivered robust revenue growth, advanced our pipeline across all 4 therapeutic areas, announced multiple business development transactions, and invested to drive our future growth,” Ricks stated.<\/p>\n
The growth story for LLY stock is far from over, given that Wall Street estimates the top-line to expand from $65 billion in 2025 to $133 billion in 2030.\u00a0<\/p>\n
Eli Lilly’s CEO Dave Ricks is bullish on expanding the company’s product portfolio.<\/p>\n
Spencer Platt/Getty Images<\/p>\n
Wall Street remains bullish on LLY stock<\/p>\n
The 22 analysts covering Eli Lilly stock have a consensus rating of “strong buy” and an average price target of $1,263 \u2014 implying more than 27% upside from current levels.<\/p>\n
One of the more bullish forecasts comes from Barclays, which recently raised its LLY stock price target to $1,400.\u00a0<\/p>\n
More on dividend stocks:Large-cap bank stock pays Warren Buffett $23M in annual dividendsEarly VIG ETF investors now earn a 6.6% yield on costCostco quietly bumps its quarterly dividend by 13%<\/p>\n
According to estimates, Zepbound and Foundayo could generate about $31 billion in combined U.S. sales next year, The Motley Fool notes, potentially rising to $45 billion by 2030.<\/p>\n
That kind of top-line trajectory, if it materializes, makes future dividend growth look very achievable.<\/p>\n
Eli Lilly has maintained an average dividend growth rate of about 15% over the past three and five years, and has raised its dividend for 12 consecutive years.<\/p>\n
If Lilly keeps growing its payout at even a fraction of that pace, early investors in this dividend stock could find their yield-on-cost climbing even higher in the years ahead.<\/p>\n
That’s the simple, powerful case for owning a great company and never selling.<\/p>\n
Related: BofA sees more upside in Eli Lilly stock<\/p>\n
#Early #Eli #Lilly #stock #investors #earn #dividend #yieldoncost<\/p>\n","protected":false},"excerpt":{"rendered":"
There’s a reason the world’s most patient investors love dividend stocks. Market movements heavily influence…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[186,451,3237,11171,92,11172,91,11456],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/5863"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5863"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/5863\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}